LLY (Eli Lilly & Co.)
Insider Trading Activity
Every open-market purchase and sale reported by LLY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-04 | Eric Dozier | EVP, Chief People Officer | G | — | — |
| 2026-09-04 | Edgardo Hernandez | EVP & Pres., Mfg. Operations | G | — | — |
| 2026-08-18 | JUAN R LUCIANO | Director | A | — | — |
| 2026-08-18 | J Erik Fyrwald | Director | A | — | — |
| 2026-08-18 | Gabrielle Sulzberger | Director | A | — | — |
| 2026-08-18 | Ralph Alvarez | Director | A | — | — |
| 2026-08-18 | Patrik Jonsson | EVP & President, LLY Int'l | Sell | — | — |
| 2026-08-11 | Donald A Zakrowski | SVP, Finance, & CAO | Sell | — | — |
| 2026-08-10 | Anat Hakim | EVP, GC & Secretary | Sell | — | — |
| 2026-08-03 | Melissa Seymour | EVP, Global Quality | MIXED | — | — |
| 2026-07-21 | Ralph Alvarez | Director | A | — | — |
| 2026-07-21 | JUAN R LUCIANO | Director | A | — | — |
| 2026-07-21 | J Erik Fyrwald | Director | A | — | — |
| 2026-07-21 | Gabrielle Sulzberger | Director | A | — | — |
| 2026-06-16 | J Erik Fyrwald | Director | A | — | — |
| 2026-06-16 | JUAN R LUCIANO | Director | A | — | — |
| 2026-06-16 | Ralph Alvarez | Director | A | — | — |
| 2026-06-16 | Gabrielle Sulzberger | Director | A | — | — |
| 2026-06-11 | Ilya Yuffa | EVP&Pres, LLY USA&Global Capab | Sell | — | — |
| 2026-05-19 | Ralph Alvarez | Director | A | — | — |
| 2026-05-19 | J Erik Fyrwald | Director | A | — | — |
| 2026-05-19 | JUAN R LUCIANO | Director | A | — | — |
| 2026-05-19 | Gabrielle Sulzberger | Director | A | — | — |
| 2026-05-07 | LILLY ENDOWMENT INC | — | Sell | — | — |
| 2026-04-21 | Ralph Alvarez | Director | A | — | — |
| 2026-04-21 | J Erik Fyrwald | Director | A | — | — |
| 2026-04-21 | JUAN R LUCIANO | Director | A | — | — |
| 2026-04-21 | Gabrielle Sulzberger | Director | A | — | — |
| 2026-03-17 | Ralph Alvarez | Director | A | — | — |
| 2026-03-17 | J Erik Fyrwald | Director | A | — | — |
| 2026-03-17 | JUAN R LUCIANO | Director | A | — | — |
| 2026-03-17 | Gabrielle Sulzberger | Director | A | — | — |
| 2026-02-19 | Eric Dozier | EVP, Chief People Officer | G | — | — |
| 2026-02-18 | Adrienne S Brown | EVP, President LLY Imm | MIXED | — | — |
| 2026-02-18 | Kenneth L. Custer | EVP & President, Card Met Hlth | MIXED | — | — |
| 2026-02-18 | Lucas Montarce | EVP & CFO | MIXED | — | — |
| 2026-02-18 | Donald A Zakrowski | SVP, Finance, & CAO | MIXED | — | — |
| 2026-02-18 | Ralph Alvarez | Director | A | — | — |
| 2026-02-18 | J Erik Fyrwald | Director | A | — | — |
| 2026-02-18 | JUAN R LUCIANO | Director | A | — | — |
| 2026-02-18 | Gabrielle Sulzberger | Director | A | — | — |
| 2026-02-12 | Diogo Rau | EVP & CIDO | A | — | — |
| 2026-02-11 | Adrienne S Brown | EVP, President LLY Imm | A | — | — |
| 2026-02-11 | Kenneth L. Custer | EVP & President, Card Met Hlth | A | — | — |
| 2026-02-11 | Eric Dozier | EVP, Chief People Officer | A | — | — |
| 2026-02-11 | Anat Hakim | EVP, GC & Secretary | A | — | — |
| 2026-02-11 | Edgardo Hernandez | EVP & Pres., Mfg. Operations | A | — | — |
| 2026-02-11 | Patrik Jonsson | EVP & President, LLY Int'l | A | — | — |
| 2026-02-11 | Lucas Montarce | EVP & CFO | A | — | — |
| 2026-02-11 | Diogo Rau | EVP & CIDO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 91,883,358 | — |
| — | President, Chair, and CEO | 579,023 | — |
| — | Chairman, President and CEO | 457,528 | — |
| — | Chairman | 441,806 | — |
| — | EVP,Science&Tech and Pres. LRL | 199,212 | — |
| — | SVP&Pres, LillyDiab & LillyUSA | 163,121 | — |
| — | EVP, CS&PO & Pres. LRL | 162,781 | — |
| — | Sr. VP and General Counsel | 154,858 | — |
| — | SVP, HR & Diversity | 152,812 | — |
| — | EVP and Pres, Lilly Bio-Meds | 145,979 | — |
| — | SVP&Pres. Elanco Animal Health | 145,566 | — |
| — | President, Mfg. Operations | 113,581 | — |
| — | Sr. VP, Corp. Affairs & Comm. | 112,518 | — |
| — | Sr.VP, Corp. Strategy & BD | 104,886 | — |
| — | SVP and CFO | 79,810 | — |
| — | Director | 77,038 | — |
| — | Director | 75,418 | — |
| — | SVP & Pres., Mfg. Operations | 74,454 | — |
| — | EVP & Pres, Lilly Neuroscience | 74,209 | — |
| — | SVP&Pres., Emerging Markets | 73,499 | — |
| — | Director | 73,166 | — |
| — | SVP, Global Quality | 70,436 | — |
| — | Director | 68,574 | — |
| — | President, Internat'l Opers. | 66,611 | — |
| — | Director | 63,789 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LLY quote page; the site-wide leaderboard is on the insider transactions hub.